Jump to Main Content
Localized Light-Au-Hyperthermia Treatment for Precise, Rapid, and Drug-Free Blood Clot Lysis
- Dong, Lina, Liu, Xiao, Wang, Tian, Fang, Bixing, Chen, Jinghuang, Li, Chen, Miao, Xinxin, Wei, Chaochao, Yu, Fen, Xin, Hongbo, Hong, Kui, Ding, Xingwei, Wang, Xiaolei
- ACS applied materials & interfaces 2018 v.11 no.2 pp. 1951-1956
- animal models, biocompatibility, blood coagulation, blood stasis, drugs, fever, gold, hematoma, mice, mortality, myocardial infarction, nanogold, nanorods, risk, therapeutics, thrombosis
- Thrombus diseases, induced by blood stasis or vascular embolization normally, frequently occur with high disability and mortalities worldwide. At present, drug thrombolysis, a primary clinical therapy for blood clot lysis, could increase the lethal risk for hemorrhage when thrombolysis agents are overused in the whole body. Therefore, a novel and advanced therapy for blood clot lysis, based on remote physical signals, is helpful for assisting clinical therapy. Here, we used the localized light-Au-hyperthermia (LAH) treatment, induced by gold nanorods (Au NRs) irradiated with near-infrared light (808 nm), for precise, rapid, and drug-free blood clot lysis. The LAH technology was first introduced in the murine hematoma model and the murine myocardial infarction model for blood clot lysis. Compared with traditional therapy, LAH was assured to shorten the time of detumescence in the murine hematoma model owing to their precise and localized hyperthermia. Meanwhile, we also discovered that LAH was a benefit to vascular recanalization in the murine myocardial infarction model. In addition, the Au NRs used in LAH present ideal biocompatibility in the murine model, which endows it to be suitable for blood clot lysis in vivo.